The study reviews the influence of KRAS, NRAS, BRAF mutations, and MSI in non-metastatic colon cancer. MSI-H is present in 15% of cases and generally predicts better outcomes than microsatellite stable (MSS) cancers. However, KRAS and BRAF mutations, typically associated with poor prognosis in MSS, show a less pronounced negative impact in MSI-H cancers, mainly affecting outcomes post-recurrence rather than immediate disease-free survival. These findings emphasize the importance of genetic profiling in clinical decision-making to optimize therapeutic strategies for colon cancer patients.
Read more: https://doi.org/10.3390/diagnostics14101001
Leave a Reply